Homepage / About us

ABOUT US

We are a Danish start-up aiming to transform the diagnosis of genetic disorders for better disease management.

 

gMendel® approach

gmendel-about-phenotyping-icon

Genotyping

​We have developed a proprietary method for high-throughput and cost-effective genotyping. By calculating fractions of reads, our diagnostic tool can identify gene mutations and chromosomal aberrations from a normal karyotype and hence recognize genetic disorders.

gmendel-about-ai-icon

AI

We harness the full power of analytics and Artificial Intelligence throughout the complete sequencing process. By using machine learning algorithms, our proprietary technology translates real-time data into accurate and meaningful results.

gmendel-about-empathy-icon

Diagnosis & Treatment

Our transformative approach bridges the gap between new generation genomic tools and their clinical implementation, providing a shorter path to accurate diagnosis and potential treatment. 

9 years horizon

Phase 0: Proof of concept

At the outset, we focused on Klinefelter syndrome, which is a chromosomal aberration difficult to diagnose. This was later on expanded to 6 chromosomal aberrations (Klinefelter, Turner, Down, Patau, Edwards, Prader-Willi/Angelman).
 
In 2019, we developed a fast (<24h), cost-effective method for bacterial DNA enrichment and tagmentation in the lab, allowing species identification and strain differentiation.
 
We partnered up with leading research teams and data scientists for further development and support in Human genomes.
gmendel-spacer

Phase 1: Intelligent diagnosis – gMendel®Test

The gMendel®Test is fully developed. Data validation has been performed in a strongly controlled environment, meeting specific quality criteria of medical protocols.

The gMendel®Test aims to address the diagnostic needs of 350 million families and 6 million births per year, paving the way “from diagnosis to treatment”.

We plan to commercialize a diagnostic tool of 32 genetic disorders, 6 universal prenatal chromosomal aberrations and 26 postnatal, comprising of the most prevalent genetic disorders with treatment in each country.

Our commercialization strategy includes direct sales in Denmark in 2022, followed by the rest of Scandinavia, the Netherlands, Spain, Greece, North Macedonia, Italy, and Switzerland in 2023 and from 2024 onwards, Germany, France, the UK, the USA, Canada, Brazil, Israel, Egypt, Turkey, UAE and Saudi Arabia.

Commercial partnerships will be carried out as gMendel® expands worldwide.

In parallel, we plan to commercialize a full genome sequencing diagnostic tool, leveraging on the full potential of the Phivea™ Platform.

Phase 2: Improving lives of people with genetic disorders and their caregivers – gMendel®Care

Our vision goes beyond technological advancement. With our gMendel®Care initiative, we aim to empower families and their children through social care and equal opportunities, and contribute to building resilient healthcare and welfare systems.

We aim to do this by including the gMendel®Test in national healthcare protocols for prenatal and postnatal diagnosis, creating synergies with pharmaceutical companies to stimulate research and development in orphan drugs, and facilitating collaboration and constructive dialogue with national health policy bodies and platforms.

gmendel-spacer

Phase 3: Intelligent treatment – gMendel®Hope

In the future, we hope to combine the gMendel® method with direct methods in protein crystallography.

Our vision is to shape successful treatment protocols on allogeneic bone marrow transplants, by identifying compatible matches to Major Histocompatibility Complex proteins, more accurately and economically.

 

Meet the team

Chris Kyriakidis

Chris
Kyriakidis

PhD, MSc, MBA
Co-founder
Kristijan Jankoski

Kristijan
Jankoski

MSc
Senior Data Scientist
Tomasz Puk

Thomasz
Puk *

MSc, MBA
Head of Q&R
Dariusz Nabiałczyk

Dariusz
Nabiałczyk *

MSc Software Architect
Head of Q&R
Zoran Velkoski

Zoran
Velkoski

MSc, MBA
Co-founder
David Galevski

David
Galevski

MSc
Data Scientist
Jaroslaw Kowalczyk

Jarosław
Kowalczyk *

MSc
Quality Assurance Manager
Agnieszka Tymoszyk

Agnieszka
Tymoszyk *

BSc
QA Engineer
Aleksandar Nikov

Aleksandar
Nikov

BSc
Head of AI
Anne Kristine Schack

Anne
Schack

MSc
Genomics Researcher
Dimitris Kyriakidis

Dimitris
Kyriakidis

MSc
Advocacy Groups
Witold Lukaszewski

Witold
Lukaszewski *

MSc
Business Analyst
Gjorgji Madjarov

Gjorgji
Madjarov *

PhD, MSc
AI Advisor
Lukasz Krych

Lukasz
Krych *

PhD, MSc
Genomics Advisor
Rafal Kalka

Rafal
Kalka *

MSc
Senior Project Manager

Maria
Andrielou *

MSc, MA
Head of Marketing & Communication
*Gjorgji: Professor at the Ss Cyril & Methodius University of Skopje
Lukasz: Associate Professor at the University of Copenhagen
Tomasz, Jarosław, Rafal, Dariusz, Agnieszka, Witold: Members of the Star.Global Team
Andrielou: Head of Marketing & Corporate Communication at Plankton First S.A.

Social responsibility

gMendel contributes to the communities where we live. We are committed to our employees, diversity, equity, inclusion, and environmental sustainability.

We have partnered with Besesaka Foundation, a non-profit organization in Bukom, Ghana, aiming to improve education through the power of boxing. Established in 2019, Besesaka aims to establish a Boxucation academy, where boxing is as important as education, by the end of 2023. Until then, Besesaka provides educational scholarships to boys and girls, who love boxing and are great at it, have excellent academic level and demonstrate a great character. Its vision is to develop a new Bukom where all children attend school and graduate, resulting in the elimination of teenage pregnancy and child labor.

Through Besesaka and Boxucation, we contribute to developing better leaders and creating equal opportunities for children, one step at a time.